ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
면역조절제 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 7.1%로 3,115억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 비침습적 치료에 대한 환자 선호도 증가, 규제 당국의 승인 및 가이드라인, 면역 조절 치료에 대한 의료 보험 적용 범위, 면역 조절 약물의 수와 발전, 정부의 의료비 지출 등에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 생명공학 및 면역치료의 발전, 연구개발 파이프라인에 있는 면역조절제의 수와 진행 상황, 기술 발전, 맞춤형 의료 트렌드, 면역종양학의 발전 등을 들 수 있습니다.
향후 5년간 7.1%의 성장률 전망은 지난번 예측보다 0.6% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰로 인해 스위스나 영국에서 개발된 JAK 억제제나 인터류킨 차단제의 가격이 급등하여 자가면역질환의 관리가 지연되고 류마티스 치료비용이 상승하여 미국의 첨단 면역치료제 도입에 장애가 될 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
만성질환의 유병률 증가는 향후 몇 년간 면역조절제 시장의 성장을 크게 견인할 것으로 예상됩니다. 만성질환은 서서히 발병하여 오랜 기간(종종 평생) 동안 지속되는 장기적인 질환입니다. 만성질환의 증가는 인구 고령화, 생활습관 선택, 유전적 소인, 의료시스템의 가용성 및 인프라 등의 요인에 의해 촉진됩니다. 면역조절제는 면역반응을 조절하고, 염증을 억제하고, 장기 거부반응을 예방하고, 면역 감시를 강화하고, 증상 조절을 개선함으로써 만성질환 관리에 중요한 역할을 합니다. 예를 들어, 2023년 9월 세계보건기구(WHO)는 전 세계 사망자의 74%를 차지하는 4,100만 명이 비감염성 질환(NCDs) 또는 만성질환으로 인한 사망자라고 보고했습니다. 그 내역은 심혈관질환으로 인한 사망이 1,790만 명, 암으로 인한 사망이 930만 명, 만성 호흡기질환으로 인한 사망이 410만 명, 당뇨병으로 인한 사망이 200만 명입니다. 그 결과, 만성질환의 부담이 증가하면서 면역조절제에 대한 수요가 증가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 면역조절제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 면역조절제 시장 : 성장률 분석
세계의 면역조절제 시장 실적 : 규모와 성장, 2019-2024
세계의 면역조절제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 면역조절제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 면역조절제 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
면역억제제
면역자극제
기타 제품 유형
세계의 면역조절제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
온라인 약국
소매 약국
기타 유통 채널
세계의 면역조절제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
종양학
호흡기
인간면역결핍바이러스
기타 용도
세계의 면역조절제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
기타 최종사용자
세계의 면역조절제 시장 : 하위 세분화 면역억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
코르티코스테로이드
칼시뉴린 억제제(타크로리무스, 사이클로스포린)
MTOR 억제제(시롤리무스, 에버롤리무스)
대사길항제(아자티오프린, 메토트렉세이트)
생물학적 면역억제제(리툭시맙 같은 단클론항체)
야누스 키나아제(JAK) 억제제
T세포 억제제
기타 면역억제제
세계의 면역조절제 시장 : 하위 세분화 면역자극제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
사이토카인 및 성장인자 기반 면역자극제(인터페론, 인터류킨)
면역 자극을 위한 단클론항체
백신(암 백신, 예방 백신)
보조제 및 면역조절제
자가면역질환에 대한 면역자극제
톨유사수용체(TLR) 작용제
핵산계 면역자극제(DNA 또는 RNA 백신)
세계의 면역조절제 시장 : 하위 세분화 기타 제품 유형(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
생물학적 제제(융합 단백질, 면역관문억제제)
저분자 면역조절제
면역치료제
줄기세포 기반 면역조절제
면역 종양약
프로바이오틱스 및 기타 천연 면역조절제
제7장 지역별·국가별 분석
세계의 면역조절제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 면역조절제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
면역조절제 시장 : 경쟁 구도
면역조절제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Sanofi S.A
Bristol Myers Squibb Company
AstraZeneca plc
Novartis AG
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Gilead Sciences Inc.
Applied Molecular Genetics Inc.
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals Inc.
Biogen Inc.
Vertex Pharmaceuticals Incorporated
UCB S.A.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
면역조절제 시장 2029 : 새로운 기회를 제공하는 국가
면역조절제 시장 2029 : 새로운 기회를 제공하는 부문
면역조절제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
An immunomodulator is a substance or medication utilized to modify or regulate the activity of the immune system, often employed in the treatment of various medical conditions. The specific application of immunomodulators varies depending on the underlying condition being addressed and the desired effect on immune response.
The primary product categories within the immunomodulator market comprise immunosuppressants, immunostimulants, and other product types. Immunosuppressants are medications designed to weaken the body's immune system, thereby reducing its capacity to combat diseases and foreign substances. These products are distributed through channels including hospital pharmacies, online pharmacies, retail pharmacies, and other distribution channels. They find application across various medical fields such as oncology, respiratory diseases, human immunodeficiency virus (HIV), among others, and are utilized by a range of end-users including hospitals, clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The immunomodulator market research report is one of a series of new reports from The Business Research Company that provides immunomodulator market statistics, including immunomodulator industry global market size, regional shares, competitors with an immunomodulator market share, detailed immunomodulator market segments, market trends, and opportunities, and any further data you may need to thrive in the immunomodulator industry. This immunomodulator research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The immunomodulator market size has grown strongly in recent years. It will grow from $219.94 billion in 2024 to $237.02 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to healthcare infrastructure development, increased awareness among patients, the aging population, increasing incidence of autoimmune diseases, and the introduction of biologic drugs.
The immunomodulator market size is expected to see strong growth in the next few years. It will grow to $311.56 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing patient preference for non-invasive, regulatory approvals and guidelines, the extent of health insurance coverage for immunomodulatory treatments, the number and progress of immunomodulatory drugs, and government healthcare expenditure. Major trends in the forecast period include advancements in biotechnology and immunotherapy, the number and progress of immunomodulatory drugs in the research and development pipeline, advances in technology, the trend towards personalized medicine, and advancements in immuno-oncology.
The forecast of 7.1% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced immunotherapies by inflating prices of JAK inhibitors and interleukin blockers developed in Switzerland and the UK, resulting in delayed autoimmune disease management and higher rheumatology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of chronic diseases is anticipated to significantly drive the growth of the immunomodulator market in the coming years. Chronic diseases are long-term medical conditions that develop gradually and persist for extended periods, often for a lifetime. The rise in chronic diseases is fueled by factors such as an aging population, lifestyle choices, genetic predispositions, and the availability and infrastructure of healthcare systems. Immunomodulators play a crucial role in managing chronic diseases by modulating immune responses, reducing inflammation, preventing organ rejection, enhancing immune surveillance, and improving symptom control. For instance, in September 2023, the World Health Organization (WHO) reported that 41 million deaths, accounting for 74% of all global deaths, were attributed to non-communicable diseases (NCDs) or chronic diseases. These included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the growing burden of chronic diseases is driving the demand for immunomodulators.
Companies in the immunomodulator market are increasingly focusing on developing non-immunosuppressive products to meet the rising demand for treatments that modulate immune responses without compromising overall immune function. Non-immunosuppressive treatments do not suppress or weaken the immune system. For example, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, commenced early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is designed to treat patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA has granted fast-track designation for NVG-2089's development in treating bullous pemphigoid. This innovative, recombinant, non-immunosuppressive immunomodulator targets type II Fc receptors to activate an endogenous regulatory mechanism that mitigates autoimmune dysregulation. The primary objective of the study is to evaluate the safety and tolerability of NVG-2089, with secondary objectives focusing on its pharmacokinetics and pharmacodynamics.
In February 2022, Equillium, Inc., a US-based biotechnology company, acquired Bioniz Therapeutics Inc. for an undisclosed amount. This acquisition significantly expanded Equillium's immunology pipeline by incorporating two first-in-class clinical-stage assets and a proprietary product discovery platform. Bioniz Therapeutics Inc., a US-based company, develops cytokine-targeted medicines for treating immuno-inflammatory disorders and cancer, which are part of the immunomodulator category. This acquisition underscores the strategic importance of expanding product portfolios to include innovative immunomodulatory treatments.
Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Ipsen SA, Kyowa Kirin Co. Ltd., Amicus Therapeutics Inc.
North America was the largest region in the immunomodulator market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the immunomodulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The immunomodulator market consists of sales of herbal immunomodulators, vaccines, immunomodulatory drugs, monoclonal antibodies, and interferons. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Immunomodulator Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on immunomodulator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for immunomodulator ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immunomodulator market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Immunosuppressants; Immunostimulants; Other Product Types
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
3) By Application: Oncology; Respiratory; Human Immunodeficiency Virus; Other Applications
4) By End-User: Hospitals; Clinics; Other End Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Immunomodulator Market Characteristics
3. Immunomodulator Market Trends And Strategies
4. Immunomodulator Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Immunomodulator Growth Analysis And Strategic Analysis Framework
5.1. Global Immunomodulator PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Immunomodulator Market Growth Rate Analysis
5.4. Global Immunomodulator Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Immunomodulator Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Immunomodulator Total Addressable Market (TAM)
6. Immunomodulator Market Segmentation
6.1. Global Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunosuppressants
Immunostimulants
Other Product Types
6.2. Global Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Distribution Channels
6.3. Global Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Respiratory
Human Immunodeficiency Virus
Other Applications
6.4. Global Immunomodulator Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End Users
6.5. Global Immunomodulator Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids
Calcineurin Inhibitors (Tacrolimus, Cyclosporine)
MTOR Inhibitors (Sirolimus, Everolimus)
Antimetabolites (Azathioprine, Methotrexate)
Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab)
Janus Kinase (JAK) Inhibitors
T-Cell Inhibitors
Other Immunosuppressive Agents
6.6. Global Immunomodulator Market, Sub-Segmentation Of Immunostimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytokine And Growth Factor-Based Immunostimulants (Interferons, Interleukins)
Monoclonal Antibodies For Immune Stimulation
Vaccines (Cancer Vaccines, Preventive Vaccines)
Adjuvants And Immune Modulatory Agents
Immunostimulatory Agents For Autoimmune Diseases
Toll-Like Receptor (TLR) Agonists
Nucleic Acid-Based Immunostimulants (DNA Or RNA Vaccines)
6.7. Global Immunomodulator Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
